MINNEAPOLIS, MN — The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, ...
SAN DIEGO, CA—Renal denervation using ultrasound may be more effective than radiofrequency ablation for lowering blood pressure in patients with resistant hypertension, a preliminary head-to-head ...
It's almost impossible to keep up with what things mean on TikTok, which is mostly thanks to the users who come up with phrases, memes, and acronyms almost daily. And when one sticks, you'd better be ...
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
SAN DIEGO, CA—Concordant with studies of other technologies for renal denervation, the presence of untreated accessory arteries was associated with a reduced blood pressure-lowering response to the ...
The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Significant predictors of persistent hypertension (HTN) 1 year after pregnancy were ...
DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results